Immune regulation by intralymphatic immunotherapy with modular allergen translocation MAT vaccine

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 69, Issue 9, 2014, Pages 1162-1170

  Zaleska, A ^a,b   Eiwegger, T ^a,c   Soyer, O ^a   Van De Veen, W ^a   Rhyner, C ^a   Soyka, M B ^a   Bekpen, C ^a,d   Demiroz D ^a,d   Treis, A ^a   Sollner S ^a   Palomares, O ^a,e   Kwok, W W ^f   Rose, H ^g   Senti, G ^h   Kundig T M ⁱ   Ozoren, N ^d   Jutel, M ^a,b   Akdis, C A ^a   Crameri, R ^a   Akdis, M ^a  

^a SWISS INSTITUTE OF ALLERGY AND ASTHMA RESEARCH SIAF   (Switzerland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d BOGAZICI UNIVERSITY   (Turkey)

^e UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^f BENAROYA RESEARCH INSTITUTE   (United States)

^g ImVisioN GmbH   (Germany)

^h UNIVERSITY HOSPITAL ZURICH   (Switzerland)

ⁱ UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

cat allergy; intralymphatic immunotherapy; modular allergen translocation; rFel d 1; tetramer

Indexed keywords

FEL D 1 PROTEIN, FELIS DOMESTICUS; GLYCOPROTEIN; VACCINE;

CLINICAL TRIAL; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DESENSITIZATION; FLOW CYTOMETRY; HUMAN; IMMUNOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE; WESTERN BLOTTING;

BLOTTING, WESTERN; DESENSITIZATION, IMMUNOLOGIC; FLOW CYTOMETRY; GLYCOPROTEINS; HUMANS; MICROSCOPY, CONFOCAL; REAL-TIME POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; VACCINES;

EID: 84905829222     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12461     Document Type: Article

References (34)

1. Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011; 127 (Suppl 1): S1-S55.
2. Calderon MA, Casale TB, Togias A, Bousquet J, Durham SR, Demoly P,. Allergen-specific immunotherapy for respiratory allergies: from meta-Analysis to registration and beyond. J Allergy Clin Immunol 2011; 127: 30-38.
3. Akdis M, Akdis CA,. Therapeutic manipulation of immune tolerance in allergic disease. Nat Rev Drug Discov 2009; 8: 645-660.
4. Crameri R, Rhyner C,. Novel vaccines and adjuvants for allergen-specific immunotherapy. Curr Opin Immunol 2006; 18: 761-768.
5. Martinez-Gomez JM, Johansen P, Erdmann I, Senti G, Crameri R, Kundig TM,. Intralymphatic injections as a new administration route for allergen-specific immunotherapy. Int Arch Allergy Immunol 2009; 150: 59-65.
6. Senti G, Prinz Vavricka BM, Erdmann I, Diaz MI, Markus R, McCormack SJ, et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci USA 2008; 105: 17908-17912.
7. Meiler F, Zumkehr J, Klunker S, Ruckert B, Akdis CA, Akdis M,. In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J Exp Med 2008; 205: 2887-2898.
8. Platts-Mills T, Vaughan J, Squillace S, Woodfolk J, Sporik R,. Sensitisation, asthma, and a modified Th2 response in children exposed to cat allergen: a population-based cross-sectional study. Lancet 2001; 357: 752-756.
9. Ichikawa K, Iwasaki E, Baba M, Chapman MD,. High prevalence of sensitization to cat allergen among Japanese children with asthma, living without cats. Clin Exp Allergy 1999; 29: 754-761.
10. Roost HP, Kunzli N, Schindler C, Jarvis D, Chinn S, Perruchoud AP, et al. Role of current and childhood exposure to cat and atopic sensitization. European Community Respiratory Health Survey. J Allergy Clin Immunol 1999; 104: 941-947.
11. Crameri R, Kundig TM, Akdis CA,. Modular antigen-translocation as a novel vaccine strategy for allergen-specific immunotherapy. Curr Opin Allergy Clin Immunol 2009; 9: 568-573.
12. Senti G, Crameri R, Kuster D, Johansen P, Martinez-Gomez JM, Graf N, et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol 2012; 129: 1290-1296.
13. Sallusto F, Lanzavecchia A,. Understanding dendritic cell and T-lymphocyte traffic through the analysis of chemokine receptor expression. Immunol Rev 2000; 177: 134-140.
14. Hirai H, Tanaka K, Yoshie O, Ogawa K, Kenmotsu K, Takamori Y, et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 2001; 193: 255-261.
15. Sadegh-Nasseri S, Natarajan S, Chou CL, Hartman IZ, Narayan K, Kim A,. Conformational heterogeneity of MHC class II induced upon binding to different peptides is a key regulator in antigen presentation and epitope selection. Immunol Res 2010; 47: 56-64.
16. Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA,. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008; 453: 1122-1126.
17. Doyle SL, Campbell M, Ozaki E, Salomon RG, Mori A, Kenna PF, et al. NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components. Nat Med 2012; 18: 791-798.
18. Bryant P, Ploegh H,. Class II MHC peptide loading by the professionals. Curr Opin Immunol 2004; 16: 96-102.
19. Momburg F, Fuchs S, Drexler J, Busch R, Post M, Hammerling GJ, et al. Epitope-specific enhancement of antigen presentation by invariant chain. J Exp Med 1993; 178: 1453-1458.
20. Crameri R, Fluckiger S, Daigle I, Kundig T, Rhyner C,. Design, engineering and in vitro evaluation of MHC class-II targeting allergy vaccines. Allergy 2007; 62: 197-206.
21. Custovic A, Simpson BM, Simpson A, Hallam CL, Marolia H, Walsh D, et al. Current mite, cat, and dog allergen exposure, pet ownership, and sensitization to inhalant allergens in adults. J Allergy Clin Immunol 2003; 111: 402-407.
22. Akdis M, Blaser K, Akdis CA,. T regulatory cells in allergy: novel concepts in the pathogenesis, prevention, and treatment of allergic diseases. J Allergy Clin Immunol 2005; 116: 961-968.
23. Akdis M, Verhagen J, Taylor A, Karamloo F, Karagiannidis C, Crameri R, et al. Immune responses in healthy and allergic Individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 2004; 199: 1567-1575.
24. Maggi L, Santarlasci V, Liotta F, Frosali F, Angeli R, Cosmi L, et al. Demonstration of circulating allergen-specific CD4+ CD25highFoxp3+ T-regulatory cells in both nonatopic and atopic individuals. J Allergy Clin Immunol 2007; 120: 429-436.
25. Akdis CA,. Therapies for allergic inflammation: refining strategies to induce tolerance. Nat Med 2012; 18: 736-749.
26. Ling EM, Smith T, Nguyen XD, Pridgeon C, Dallman M, Arbery J, et al. Relation of CD4+ CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet 2004; 363: 608-615.
27. Radulovic S, Jacobson MR, Durham SR, Nouri-Aria KT,. Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J Allergy Clin Immunol 2008; 121: 1467-1472.
28. Orihara K, Narita M, Tobe T, Akasawa A, Ohya Y, Matsumoto K, et al. Circulating Foxp3+ CD4+ cell numbers in atopic patients and healthy control subjects. J Allergy Clin Immunol 2007; 120: 960-962.
29. Karlsson MR, Rugtveit J, Brandtzaeg P,. Allergen-responsive CD4+ CD25+ regulatory T cells in children who have outgrown cow's milk allergy. J Exp Med 2004; 199: 1679-1688.
30. Thurmond RL, Gelfand EW, Dunford PJ,. The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines. Nat Rev Drug Discov 2008; 7: 41-53.
31. Kunzmann S, Mantel PY, Wohlfahrt JG, Akdis M, Blaser K, Schmidt-Weber CB,. Histamine enhances TGF-beta1-mediated suppression of Th2 responses. FASEB J 2003; 17: 1089-1095.
32. Muller UR, Jutel M, Reimers A, Zumkehr J, Huber C, Kriegel C, et al. Clinical and immunologic effects of H1 antihistamine preventive medication during honeybee venom immunotherapy. J Allergy Clin Immunol 2008; 122: 1001-1007.
33. Bromley SK, Mempel TR, Luster AD,. Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat Immunol 2008; 9: 970-980.
34. Kerstan A, Albert C, Klein D, Brocker EB, Trautmann A,. Wasp venom immunotherapy induces activation and homing of CD4(+)CD25(+) forkhead box protein 3-positive regulatory T cells controlling T(H)1 responses. J Allergy Clin Immunol 2011; 127: 495-501.